Supriya Lifescience Ltd Q1 FY27 Earnings Analysis

- Supriya Lifescience targets approximately 20% annual revenue growth, aiming to achieve INR 1,000 crores by FY27. - Growth driven by sustained demand in core therapeutic segments: anesthetics, antibiotics, anti-anxiety, vitamins, and ADHD. - Plan to launch 3 to 4 new products annually, including 2 new launches each in anesthetics and ADHD segments in FY27. - Cardiovascular advanced intermediate product scaling up, expected to contribute increasingly over 2-3 years. - New capacities from debottlenecking and new blocks (F block and expansions) will add 150-200 KL over 2 years to support growth. - Backward integration completed to support scalability and cost efficiency. - Ambernath and upcoming Patalganga facilities expected to accelerate growth beyond FY27. - Growth in U.S. market exposure expected to increase over next 3-4 years through new product launches. - EBITDA margin guidance maintained at 33% to 35%, supporting profitable expansion.

- Supriya Lifescience targets approximately 20% annual revenue growth, aiming to reach INR1,000 crores by FY27. - EBITDA margins are expected to remain stable in the 33%-35% range over the next 5-6 years. - Growth will be driven by new product launches (3-4 annually), expanding regulated market exposure, and capacity expansions at Ambernath and Patalganga facilities. - R&D investments have doubled, focusing on niche APIs, CMO/CDMO opportunities, and finished formulations like liquid anesthetics and injectables. - Operating leverage expected to improve once Ambernath and Patalganga facilities are fully operational, supporting scale-up and margin stability. - Cash flow conversion may improve as inventory days normalize post backward integration scale-up. - EPS growth is aligned with revenue and margin growth, supported by disciplined cost management and expanding exports, especially in Europe and LATAM.

- Continued capacity expansion with the addition of the F block at Lote Parshuram plant, adding 150-200 KL capacity over the next 2 years with INR40-50 crores capex. - Development of the Patalganga facility with all clearances received; Phase 1 includes two API/advanced intermediate blocks and two formulation blocks, planned capex around INR200 crores over the next 2 years. - Focus on capacity building to support growth, especially for CMO/CDMO opportunities and to handle scaling product volumes. - Total capex for FY26 was INR152 crores, mainly spent on Ambernath facility, maintenance, Ribo Block, and formulation plant needs. - R&D investments have doubled with new labs at Lote and Ambernath focusing on new APIs, formulations, and CMO/CDMO areas. - Further capex expected to support backing integration, new product launches, and strategic growth segments like cardiovascular and anesthetics.

- No specific mention of new fundraising through debt or equity in the transcript. - The company reported that for the full year FY26, they did not utilize any working capital limits except letters of credit and bank guarantees. - Capex for FY26 was INR152 crores funded internally, focusing on Ambernath and smaller projects. - For the Patalganga facility, an estimated capex of INR200 crores is planned over the next 2 years. - No discussion on raising new debt or equity to fund this; emphasis appears on internal accruals and disciplined financial management. - Overall, no indication or announcement of fresh fundraising via debt or equity in the near term from the transcripts provided.

- Cardiovascular intermediate: Advanced discussions for 300 metric tons capacity, expected to be nearly fully utilized in FY27, but full potential to scale over 2-3 years. - Contracts locked with 3-4 large customers for the cardiovascular product. - Liquid anesthetic (sevoflurane formulation): CMO discussions at advanced stage, but no firm term sheet signed yet. - DSM contract stabilized with around 3 tons/month volume; contributing approx. INR30-35 crores in FY26 with peak expected at INR60 crores in FY27. - No signed agreement yet for GLP-1 product development; discussions are at an advanced stage. - New product launches and existing basket growing steadily. - No use of PLI scheme; focusing on customer qualification and dossier inclusion. - Order book for cardiovascular and other products contributing to gradual scale-up but no immediate large jumps in revenue for FY27 from new technologies/products.